<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="1687 PEBBLES study protocol: a randomised controlled trial to prevent" exact="atopic dermatitis," post="food allergy and sensitisation in infants with a family"/>
 <result pre="study protocol: a randomised controlled trial to prevent atopic dermatitis," exact="food allergy" post="and sensitisation in infants with a family history of"/>
 <result pre="protocol: a randomised controlled trial to prevent atopic dermatitis, food" exact="allergy" post="and sensitisation in infants with a family history of"/>
 <result pre="impaired skin barrier function increases the risk of allergic sensitisation," exact="atopic dermatitis" post="(AD) and food allergy. We hypothesise that regular prophylactic"/>
 <result pre="skin barrier function increases the risk of allergic sensitisation, atopic" exact="dermatitis" post="(AD) and food allergy. We hypothesise that regular prophylactic"/>
 <result pre="increases the risk of allergic sensitisation, atopic dermatitis (AD) and" exact="food allergy." post="We hypothesise that regular prophylactic use of emollients, particularly"/>
 <result pre="two times per day reduces the risk of AD and" exact="food allergy," post="we have commenced a multicentre phase III, outcome assessor"/>
 <result pre="of AD, assessed using the UK Working Party criteria, and" exact="food allergy" post="using food challenge, in the first 12 months of"/>
 <result pre="AD, assessed using the UK Working Party criteria, and food" exact="allergy" post="using food challenge, in the first 12 months of"/>
 <result pre="registration numbers ACTRN12617001380381 and NCT03667651. eczema paediatric dermatology paediatric dermatology" exact="allergy" post="asthma Funding http://dx.doi.org/10.13039/501100000925 National Health and Medical Research Council"/>
 <result pre="numbers ACTRN12617001380381 and NCT03667651. eczema paediatric dermatology paediatric dermatology allergy" exact="asthma" post="Funding http://dx.doi.org/10.13039/501100000925 National Health and Medical Research Council Strengths"/>
 <result pre="application of a ceramide-dominant emollient two times per day on" exact="atopic dermatitis" post="and food allergy. Using this emollient may maximise the"/>
 <result pre="of a ceramide-dominant emollient two times per day on atopic" exact="dermatitis" post="and food allergy. Using this emollient may maximise the"/>
 <result pre="ceramide-dominant emollient two times per day on atopic dermatitis and" exact="food allergy." post="Using this emollient may maximise the effectiveness of this"/>
 <result pre="available. Given the accumulating evidence on the link between infant" exact="atopic dermatitis" post="(AD) and increased risk of developing food allergy, 2"/>
 <result pre="Given the accumulating evidence on the link between infant atopic" exact="dermatitis" post="(AD) and increased risk of developing food allergy, 2"/>
 <result pre="between infant atopic dermatitis (AD) and increased risk of developing" exact="food allergy," post="2 asthma 3 and allergic rhinitis, there is increasing"/>
 <result pre="dermatitis (AD) and increased risk of developing food allergy, 2" exact="asthma" post="3 and allergic rhinitis, there is increasing interest in"/>
 <result pre="increased risk of developing food allergy, 2 asthma 3 and" exact="allergic rhinitis," post="there is increasing interest in investigating whether improving skin"/>
 <result pre="investigating the role of AD in the development of sensitisation," exact="food allergy" post="and asthma both in childhood 2–5 and into adulthood."/>
 <result pre="the role of AD in the development of sensitisation, food" exact="allergy" post="and asthma both in childhood 2–5 and into adulthood."/>
 <result pre="of AD in the development of sensitisation, food allergy and" exact="asthma" post="both in childhood 2–5 and into adulthood. 6 7"/>
 <result pre="of allergy, there is no definitive proof that AD causes" exact="food allergy," post="hay fever or asthma, as these conditions may be"/>
 <result pre="ceased, (ii) this form of intervention reduces the incidence of" exact="food allergy" post="or later asthma and allergic rhinitis and (iii) such"/>
 <result pre="(ii) this form of intervention reduces the incidence of food" exact="allergy" post="or later asthma and allergic rhinitis and (iii) such"/>
 <result pre="of intervention reduces the incidence of food allergy or later" exact="asthma" post="and allergic rhinitis and (iii) such treatments are effective"/>
 <result pre="reduces the incidence of food allergy or later asthma and" exact="allergic rhinitis" post="and (iii) such treatments are effective in both those"/>
 <result pre="the incidence of food allergy or later asthma and allergic" exact="rhinitis" post="and (iii) such treatments are effective in both those"/>
 <result pre="incidence of AD beyond the treatment period, and measurement of" exact="food allergy" post="outcomes, are urgently needed. A number of such trials"/>
 <result pre="of AD beyond the treatment period, and measurement of food" exact="allergy" post="outcomes, are urgently needed. A number of such trials"/>
 <result pre="a slightly acidic pH (5.0), similar to mature skin, which" exact="aids" post="the production and secretion of ceramides by the skin."/>
 <result pre="beyond the active treatment period, or reduces the prevalence of" exact="food allergy" post="and allergic sensitisation. This study follows on from our"/>
 <result pre="the active treatment period, or reduces the prevalence of food" exact="allergy" post="and allergic sensitisation. This study follows on from our"/>
 <result pre="two times per day reduces the risk of AD and" exact="food allergy" post="by 12 months of age, when compared with standard"/>
 <result pre="times per day reduces the risk of AD and food" exact="allergy" post="by 12 months of age, when compared with standard"/>
 <result pre="emollient on the primary outcomes of incidence of AD and" exact="food allergy" post="in high risk infants. Setting and participants Treatment will"/>
 <result pre="on the primary outcomes of incidence of AD and food" exact="allergy" post="in high risk infants. Setting and participants Treatment will"/>
 <result pre="be eligible to ensure a high rate of AD and" exact="food allergy." post="Infants will be eligible to participate if at least"/>
 <result pre="history of at least one of asthma, eczema/AD, hay fever/allergic" exact="rhinitis" post="or food allergy. Infants will be enrolled up to"/>
 <result pre="at least one of asthma, eczema/AD, hay fever/allergic rhinitis or" exact="food allergy." post="Infants will be enrolled up to 3 weeks of age."/>
 <result pre="following will be excluded: a parent who has a known" exact="hypersensitivity" post="to any of the ingredients of EpiCeram, multiple births,"/>
 <result pre="of Clinical Immunology and Allergy’s (ASCIA) advice on strategies for" exact="allergy" post="prevention ( https://www.allergy.org.au/patients/allergy-prevention/ascia-guidelines-for-infant-feeding-and-allergy-prevention). This advice, updated in 2016, recommends"/>
 <result pre="history of dry skin since birth and (iii) visible flexural" exact="dermatitis" post="(note-all children will have a family history of allergic"/>
 <result pre="have a family history of allergic disease). Confirmed diagnosis of" exact="food allergy" post="at 12 months. This diagnosis is derived from a"/>
 <result pre="a family history of allergic disease). Confirmed diagnosis of food" exact="allergy" post="at 12 months. This diagnosis is derived from a"/>
 <result pre="FLG null mutations and other mutations related to AD and" exact="food allergy" post="risk 29 will be examined. Tape stripping Lipids and"/>
 <result pre="null mutations and other mutations related to AD and food" exact="allergy" post="risk 29 will be examined. Tape stripping Lipids and"/>
 <result pre="and (2) 80% power to detect a 7.5% reduction in" exact="food allergy" post="at 12 months (from 15% to 7.5%, RR=0.5). As"/>
 <result pre="(2) 80% power to detect a 7.5% reduction in food" exact="allergy" post="at 12 months (from 15% to 7.5%, RR=0.5). As"/>
 <result pre="of AD (including 6 months after the cessation of treatment) and" exact="food allergy." post="The study findings will help determine if maintenance of"/>
 <result pre="and may inform primary prevention strategies. Allergic diseases, including AD," exact="food allergy," post="allergic rhinitis and allergic asthma are highly prevalent in"/>
 <result pre="inform primary prevention strategies. Allergic diseases, including AD, food allergy," exact="allergic rhinitis" post="and allergic asthma are highly prevalent in Westernised countries,"/>
 <result pre="primary prevention strategies. Allergic diseases, including AD, food allergy, allergic" exact="rhinitis" post="and allergic asthma are highly prevalent in Westernised countries,"/>
 <result pre="strategies. Allergic diseases, including AD, food allergy, allergic rhinitis and" exact="allergic asthma" post="are highly prevalent in Westernised countries, and are increasingly"/>
 <result pre="Allergic diseases, including AD, food allergy, allergic rhinitis and allergic" exact="asthma" post="are highly prevalent in Westernised countries, and are increasingly"/>
 <result pre="of FLG null mutations in the aetiology of AD and" exact="food allergy" post="is robust, there are other genes that have also"/>
 <result pre="FLG null mutations in the aetiology of AD and food" exact="allergy" post="is robust, there are other genes that have also"/>
 <result pre="23 This is a commonly used definition and includes flexural" exact="rash" post="that is observed by an assessor blinded to the"/>
 <result pre="with blinded outcome assessment, and including food challenges to confirm" exact="food allergy." post="The study will be conducted in Melbourne, Australia, where"/>
 <result pre="Australia, where there are high rates of AD 48 and" exact="food allergy." post="49 Inclusion of only infants with a family history"/>
 <result pre="disease will increase the baseline prevalence of AD 48 and" exact="food allergy," post="50 which will maximise the statistical power to detect"/>
 <result pre="beyond the active treatment period and prevent the development of" exact="food allergy" post="and allergic sensitisation. To date, there are no proven"/>
 <result pre="the active treatment period and prevent the development of food" exact="allergy" post="and allergic sensitisation. To date, there are no proven"/>
 <result pre="the potential to help reduce the burden of AD and" exact="food allergy." post="Ethics and dissemination Protocol amendments will be submitted to"/>
 <result pre="breast milk assays). MT and KJA developed the protocol for" exact="food allergy" post="outcomes, while JS and GV developed the skin and"/>
 <result pre="milk assays). MT and KJA developed the protocol for food" exact="allergy" post="outcomes, while JS and GV developed the skin and"/>
 <result pre="allergy outcomes, while JS and GV developed the skin and" exact="atopic dermatitis" post="outcome assessments. MA and CFR developed the plans for"/>
 <result pre="outcomes, while JS and GV developed the skin and atopic" exact="dermatitis" post="outcome assessments. MA and CFR developed the plans for"/>
 <result pre="et al. Which infants with eczema are at risk of" exact="food allergy?" post="Results from a population-based cohort . Clin Exp Allergy"/>
 <result pre="MC , Gurrin L , et al. Childhood eczema and" exact="rhinitis" post="predict atopic but not nonatopic adult asthma: a prospective"/>
 <result pre="SC , Byrnes GB , et al. Childhood eczema and" exact="asthma" post="incidence and persistence: a cohort study from childhood to"/>
 <result pre=", Lowe AJ , Matheson MC , et al. Atopic" exact="dermatitis" post="and the atopic march revisited. Allergy 2014; 69: 17–"/>
 <result pre="loss at 2 days and 2 months predates and predicts" exact="atopic dermatitis" post="at 1 year . J Allergy Clin Immunol 2015;"/>
 <result pre="at 2 days and 2 months predates and predicts atopic" exact="dermatitis" post="at 1 year . J Allergy Clin Immunol 2015;"/>
 <result pre="of a barrier lipid replacement strategy for the prevention of" exact="atopic dermatitis" post="and allergic sensitization: the PEBBLES pilot study . Br"/>
 <result pre="a barrier lipid replacement strategy for the prevention of atopic" exact="dermatitis" post="and allergic sensitization: the PEBBLES pilot study . Br"/>
 <result pre="Emollient enhancement of the skin barrier from birth offers effective" exact="atopic dermatitis" post="prevention . J Allergy Clin Immunol 2014; 134: 818–"/>
 <result pre="enhancement of the skin barrier from birth offers effective atopic" exact="dermatitis" post="prevention . J Allergy Clin Immunol 2014; 134: 818–"/>
 <result pre="et al. Application of moisturizer to neonates prevents development of" exact="atopic dermatitis." post="J Allergy Clin Immunol 2014; 134: 824– 30. 10.1016/j.jaci.2014.07.060"/>
 <result pre="Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric" exact="atopic dermatitis" post=". J Drugs Dermatol 2009; 8: 1106– 11. 20027938"/>
 <result pre="of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic" exact="dermatitis" post=". J Drugs Dermatol 2009; 8: 1106– 11. 20027938"/>
 <result pre="eczema area and severity index (EASI): assessment of reliability in" exact="atopic dermatitis." post="EASI Evaluator Group . Exp Dermatol 2001; 10: 11–"/>
 <result pre="JR , et al. How should an incident case of" exact="atopic dermatitis" post="be defined? A systematic review of primary prevention studies"/>
 <result pre=", et al. How should an incident case of atopic" exact="dermatitis" post="be defined? A systematic review of primary prevention studies"/>
 <result pre="al. Validation of the Eczema Area and Severity Index for" exact="atopic dermatitis" post="in a cohort of 1550 patients from the pimecrolimus"/>
 <result pre="Validation of the Eczema Area and Severity Index for atopic" exact="dermatitis" post="in a cohort of 1550 patients from the pimecrolimus"/>
 <result pre="et al. Epidermal thymic stromal lymphopoietin predicts the development of" exact="atopic dermatitis" post="during infancy . J Allergy Clin Immunol 2016; 137:"/>
 <result pre="al. Epidermal thymic stromal lymphopoietin predicts the development of atopic" exact="dermatitis" post="during infancy . J Allergy Clin Immunol 2016; 137:"/>
 <result pre="et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to" exact="atopic dermatitis" post="flare . Nat Microbiol 2016; 1: 16106 10.1038/nmicrobiol.2016.106 27562258"/>
 <result pre="al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic" exact="dermatitis" post="flare . Nat Microbiol 2016; 1: 16106 10.1038/nmicrobiol.2016.106 27562258"/>
 <result pre="skin barrier and microbes in infants at risk for developing" exact="atopic dermatitis" post=". PLoS One 2018; 13: e0192443 10.1371/journal.pone.0192443 29489859 33."/>
 <result pre="barrier and microbes in infants at risk for developing atopic" exact="dermatitis" post=". PLoS One 2018; 13: e0192443 10.1371/journal.pone.0192443 29489859 33."/>
 <result pre="epidermal barrier protein filaggrin are a major predisposing factor for" exact="atopic dermatitis" post=". Nat Genet 2006; 38: 441– 6. 10.1038/ng1767 16550169"/>
 <result pre="barrier protein filaggrin are a major predisposing factor for atopic" exact="dermatitis" post=". Nat Genet 2006; 38: 441– 6. 10.1038/ng1767 16550169"/>
 <result pre="et al. Loss-of-function mutations in the gene encoding filaggrin cause" exact="ichthyosis vulgaris." post="Nat Genet 2006; 38: 337– 42. 10.1038/ng1743 16444271 41."/>
 <result pre="RL , et al. Wide spectrum of filaggrin-null mutations in" exact="atopic dermatitis" post="highlights differences between Singaporean Chinese and European populations ."/>
 <result pre=", et al. Wide spectrum of filaggrin-null mutations in atopic" exact="dermatitis" post="highlights differences between Singaporean Chinese and European populations ."/>
 <result pre="JJ , et al. Filaggrin loss-of-function mutations do not predict" exact="food allergy" post="over and above the risk of food sensitization among"/>
 <result pre=", et al. Filaggrin loss-of-function mutations do not predict food" exact="allergy" post="over and above the risk of food sensitization among"/>
 <result pre="skin barrier function gene SPINK5 is associated with challenge-proven IgE-mediated" exact="food allergy" post="in infants . Allergy 2017; 72: 1356– 64. 10.1111/all.13143"/>
 <result pre="barrier function gene SPINK5 is associated with challenge-proven IgE-mediated food" exact="allergy" post="in infants . Allergy 2017; 72: 1356– 64. 10.1111/all.13143"/>
 <result pre="Paller AS , et al. What’s in a name? Atopic" exact="dermatitis" post="or atopic eczema, but not eczema alone. Allergy 2017;"/>
 <result pre="Skin prick test can identify eczematous infants at risk of" exact="asthma" post="and allergic rhinitis. Clin Exp Allergy 2007; 37: 1624–"/>
 <result pre="test can identify eczematous infants at risk of asthma and" exact="allergic rhinitis." post="Clin Exp Allergy 2007; 37: 1624– 31. 10.1111/j.1365-2222.2007.02822.x 17877754"/>
 <result pre=", Martin PE , et al. Prevalence of challenge-proven IgE-mediated" exact="food allergy" post="using population-based sampling and predetermined challenge criteria in infants"/>
 <result pre="Martin PE , et al. Prevalence of challenge-proven IgE-mediated food" exact="allergy" post="using population-based sampling and predetermined challenge criteria in infants"/>
 <result pre="LC , et al. The impact of family history of" exact="allergy" post="on risk of food allergy: a population-based study of"/>
</results>
